67881-98-5Relevant articles and documents
Composition containing orlistat and GLP-1 receptor agonist, and use thereof
-
, (2019/01/08)
The invention belongs to the technical field of medicines, and concretely relates to a composition containing orlistat and a GLP-1 receptor agonist, and a use thereof. The composition containing orlistat and the GLP-1 receptor agonist contains orlistat, and nano-particles comprising the GLP-1 receptor agonist and a copolymer. The composition containing orlistat and the GLP-1 receptor agonist has the advantages of realization of combined oral administration of orlistat and the GLP-1 receptor agonist, high bioavailability and good weight gain increase-inhibiting and weight-reducing effects.
Application of nanoparticle containing orlistat in preparing anti-hepatitis B virus medicine
-
Paragraph 0084; 0085; 0088, (2018/10/11)
The invention relates to the technical field of medicines, in particular to application of a nanoparticle containing orlistat in preparing an anti-hepatitis B virus (HBV) medicine. The nanoparticle isprepared from the orlistat and a copolymer chosen from a vitamin A methacrylate-2-methacryloyloxyethyl phosphorylcholine copolymer or a vitamin E methacrylate-2-methacryloyloxyethyl phosphorylcholinecopolymer or a vitamin D2 methacrylate-2-methacryloyloxyethyl phosphorylcholine copolymer. The encapsulation efficiency of the nanoparticle is 82.67-93.83%; animal test shows that after oral administration of the nanoparticle, the blood drug concentration is higher, and the sustained-release effect is good; an in-vitro test result shows that the inhibition ratio of extracellular HBV DNA replication is used as an index, and the activity of the nanoparticle for resisting HBV infection is significantly higher than those of the orlistat and a contrast nanoparticle prepared by adopting PMB30W as acarrier.
Synthetic method of artificial cytomembrane main ingredient 2-methacryloyloxy ethyl phosphorylcholine
-
Paragraph 0020; 0021; 0022; 0023; 0024; 0025, (2017/10/12)
The invention provides a synthetic method of artificial cytomembrane main ingredient 2-methacryloyloxy ethyl phosphorylcholine. The synthetic method comprises the following steps: (1) dissolving phosphorus oxychloride in acetonitrile, adding triethylamine at 0 to 10 DEG C, dropwise adding 2,3-dibromo-2-hydroxyethyl methacrylate, reacting at -10 to 0 DEG C, adding triethylamine and choline chloride to facilitate the reaction at -10 to 0 DEG C, and obtaining bromophosphorylcholine after the reaction is ended; and (2) dissolving the bromophosphorylcholine obtained in the step (1) in ethanol, adding zinc powder, severely stirring, and obtaining 2-methacryloyloxyethyl phosphorylcholine. By adopting the synthetic method, a synthetic route of the original 2-methacryloyloxyethyl phosphorylcholine is simplified, no treatment is needed after the purification during the synthetic route, and the next operation can be directly carried out; severe conditions in the synthetic route are avoided, high-end equipment is not needed, uncontrollable factors during the synthetic route are reduced; raw materials are easy to obtain, the price is low, the cost is reduced, the use of solvents and raw materials with large toxicity is avoided, and the green synthesis is realized; and a foundation is set for the industrialization of the 2-methacryloyloxyethyl phosphorylcholine.